Taysha Gene Therapies, Inc. Quarterly Liabilities and Equity in USD from Q4 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Taysha Gene Therapies, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2019 to Q3 2024.
  • Taysha Gene Therapies, Inc. Liabilities and Equity for the quarter ending September 30, 2024 was $180M, a 7.94% decline year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $180M -$15.6M -7.94% Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $200M +$119M +146% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $153M +$51.4M +50.6% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $173M +$46.5M +36.8% Dec 31, 2023 10-Q 2024-11-13
Q3 2023 $196M +$84.3M +75.6% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $81.5M -$60.8M -42.7% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $102M -$64.4M -38.8% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $126M -$87.7M -41% Dec 31, 2022 10-K 2024-03-19
Q3 2022 $111M -$130M -53.8% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $142M -$99.5M -41.2% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $166M -$76.9M -31.6% Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $214M -$44.9M -17.4% Dec 31, 2021 10-K 2023-03-28
Q3 2021 $241M -$38.2M -13.7% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $242M Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $243M Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $259M +$259M Dec 31, 2020 10-K 2022-03-31
Q3 2020 $279M Sep 30, 2020 10-Q 2020-11-12
Q4 2019 $15K* Dec 31, 2019 10-K 2021-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.